Linzess Dosage/Direction for Use

The recommended dose is one capsule (290 micrograms) once daily.
Physicians should periodically assess the need for continued treatment. The efficacy of linaclotide has been established in double-blind placebo-controlled studies for up to 6 months. If patients have not experienced improvement in their symptoms after 4 weeks of treatment, the patient should be re-examined and the benefit and risks of continuing treatment reconsidered.
Special populations: Patients with renal or hepatic impairment: No dose adjustments are required for patients with hepatic or renal impairment (see Pharmacology: Pharmacokinetics under Actions).
Elderly patients: For elderly patients, although no dose adjustment is required the treatment should be carefully monitored and periodically re-assessed (see Precautions).
Paediatric population: The safety and efficacy of linaclotide in children aged 0 to18 years have not yet been established. No data are available.
LINZESS should not be used in children and adolescents (see Pharmacology: Pharmacodynamics under Actions and Precautions).
Method of administration: Oral use. The capsule should be taken at least 30 minutes before a meal (see Interactions).